Innovative Drug R&D for Chinese Pharmaceutical Companies
Over past three years, the significant changes in Chinese drug regulatory policy have brought many opportunities and challenges. This talk will focus on the new business model and research model to carry out innovative drug R&D in current circumstance, which will provide a perspective on First-in-China, Best-in-Class and First-in-Class drug discovery and development for Chinese pharmaceutical companies.
Dr. Jian Li received his BS (1982) and PhD (1987) in Chemistry from Peking University. After postdoc training in Scripps Research Institute, he worked for Texas Biotech Corp (Encysive Pharmaceuticals) and Johnson & Johnson Pharmaceutical R&D. He joined WuXi AppTec in 2008 to build up the integrative drug discovery platform, and currently is the Vice President of Domestic Discovery Service Unit (DDSU). He has published 90 scientific papers in top journals and 170 issued NCE patents and patent applications.